DEALS

Zhong Lun Advises on Zai Lab’s Secondary Listing in Hong Kong

Release time：2020-09-28 Voice Announcements

On September 28, 2020, Zai Lab Limited (9688.HK, Nasdaq: ZLAB) announced its offering and secondary listing on the Main Board of The Stock Exchange of Hong Kong Limited, and became the first innovative biopharmaceutical company that completed the secondary listing in Hong Kong. The net proceeds from this offering exceeded HK$5.7 billion prior to the exercise of the over-allotment option. J.P. Morgan, Goldman Sachs and Citi Group acted as the joint sponsors for the offering.

Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company with a focus on discovering, licensing, developing and commercializing therapies that address areas of large unmet medical need in the China and global markets, including the fields of oncology, infectious and autoimmune diseases. Zai Lab completed its IPO on the Nasdaq in September 2017, less than three years since its inception, and has developed into one of the first biopharmaceutical companies in China to scale.

Zhong Lun Law Firm acted as the issuer’s PRC legal counsel in this offering. The legal team from Zhong Lun was led by Anthony Zhao and William Jia, and included Roy Zheng, Lindsay Zhang, etc. The Zhong Lun team had also advised Zai Lab Limited on its IPO and several follow-on offerings on the Nasdaq.

Previous：Zhong Lun Advised Nucarf on Strategic Acquisition and PE Financing Next：Zhong Lun Assisted Beijing Konruns Pharmaceutical Co., Ltd. with the Acquisition of NT Pharma International Company Limited

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Assists Multiple Humanoid Robot and Intelligent Equipment Science and Technology Companies and Investors in Completing Tens of Millions Yuan Financing and Investment

Zhong Lun Advises on CR Beverage’s IPO in Hong Kong

Events

Awards

Zhong Lun Advises on Zai Lab’s Secondary Listing in Hong Kong